Abstract: Liver fibrosis is a common response to many chronic liver diseases. The aim of our study was to explore whether pharmacotherapy for concurrent diseases affects overall mortality, liver-related mortality and liver-related morbidity in patients with chronic liver disease. We performed a register-based cohort study of all patients with a first-time diagnosis of chronic liver disease between 2005 and 2012 in Sweden (n = 70 546). Data from the Patient Register, the Prescribed Drug Register and the Death Certificate Register were linked. We studied whether the use of statins, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and antibiotics affected the risk of total mortality, liver-specific mortality and morbidity. We found a reduction in mortality risk for statin users (n = 11,245) with hazard ratios from 0.57 (95% CI: 0.32-0.99) for patients with autoimmune hepatitis to 0.84 (95% CI: 0.75-0.95) for patients with alcoholic liver disease. There was a significantly reduced liver-related mortality for patients with alcoholic liver disease who used angiotensin-converting enzyme inhibitors, 0.85 (95% CI: 0.65-0.96). There were increased overall mortality risks for antibiotic users (n = 44,572), with hazard ratios up to 1.67 (95% CI, 1.55-1.80) for viral hepatitis. Statin use was associated with decreased risks of liver-specific mortality and morbidity, and reduced total mortality foremost among patients with alcoholic liver disease. Angiotensin -converting enzyme inhibitors was associated with reduced liver-related mortality among patients with alcoholic liver disease.
Liver fibrosis is a common response to many liver diseases, such as hepatitis B and C (HBV and HCV), alcohol-induced liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) [1] [2] [3] . Liver disease is the 14th most common cause of death in adults worldwide but the fourth in central Europe; it results in 1.03 million deaths per year worldwide, 170,000 per year in Europe and 33,539 per year in the United States [4] [5] [6] .
Liver fibrosis progression to liver cirrhosis may lead to liver decompensation with ascites, oesophageal varices, hepatic encephalopathy and/or hepatocellular carcinoma [7] . Liver fibrosis and even cirrhosis may be reversible with treatment of the underlying disease, for example antiviral treatment of chronic viral hepatitis, phlebotomy treatment of hereditary haemochromatosis, corticosteroids in AIH or weight reduction in NAFLD. Although therapies targeted at the underlying aetiology have been used for decades, the prognosis of chronic liver disease in general in Sweden has not improved [8] .
Future specific therapies may reduce fibrosis progression, but no such therapy is currently used in clinical practice [9] .
Whether medications such as statins, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) have any positive effects on liver disease progression is currently unknown. The aim of our study was to explore whether pharmacotherapy of other diseases could affect overall mortality, liver-related mortality and liver-related morbidity in patients with chronic liver disease.
Methods
The Patient Register at the Swedish National Board of Health and Welfare was used to identify all patients diagnosed with chronic liver diseases, hospitalized patients and outpatients at hospital clinics in Sweden, between 1 July 2005 and 31 December 2012. We used the International Classification of Diseases, 10th Revision (ICD-10) for classification of all patients with chronic liver diseases and viral hepatitis, B18 and K70-77 [10] . The ICD-10 has been in use in Sweden since 1997. Patients with incomplete personal identity numbers were excluded before the cohort was created (n = 5155). We defined and categorized the chronic liver diseases into groups: alcoholic liver disease (defined as K70), viral hepatitis (B18), autoimmune hepatitis (K73.0-9 and K75.4), primary biliary cirrhosis (K74.3), NAFLD (K76), toxic (K71) and others (K72, K74.0-2, K74.5-6, K72.0-72.9, K74.0-74.6, K75.0-K75.9 and K76.1-77.8), according to ICD-10.
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Exposure. We used the unique personal identity number assigned to all Swedish residents to link information about dispensed prescribed drugs from the Swedish Prescribed Drug Register (SPDR). Data were anonymized after the linking was carried out [11] . Drug groups of interest were defined after considering a pilot study in which we examined all drugs dispensed to patients with chronic liver diseases. We decided on the drug groups after evaluating the frequency of dispensed drugs and previous and ongoing studies evaluating possible positive effects on liver fibrosis progression. The drugs were classified according to the Anatomical Therapeutic Chemical classification (ATC codes): statins (C10AA), ACEi (C09A, C09B) and ARB (C09C, C09D) and antibiotics (J01). The frequencies of dispensed drugs are presented in Table S1 .
Exposure was treated as a time-varying covariate. A patient was considered as exposed from the second dispensation of the drug. A patient who was unexposed at diagnosis could later be classified as exposed, that is after having been dispensed drugs as defined above. All patients in the different diagnosis groups and their characteristics, both exposed and unexposed, are presented in table 1.
Outcome. Outcome measures were defined as overall mortality, liverrelated mortality and liver-related morbidity. Overall mortality was defined as being registered as deceased in the Death Certificate Register during the study period, all causes of death included. Liverrelated mortality was defined as being registered as deceased during the study period with a liver diagnosis (according to the same ICD-10 codes as we previously defined our patients) either as primary or as secondary cause of death, or having oesophageal varices (I85.0 or I85.9) or liver cancer (C22.0) as primary or secondary cause of death. Liver-related morbidity was defined as being registered in the Patient Register as hospitalized or registered in an outpatient service in a hospital with the same diagnoses as we used to define the liver-related mortality.
The Regional Ethical Review Board in Stockholm approved the study, and as this was an anonymized register study, no informed consent was obtained (dnr: 2013/988-31/1).
Statistical analyses.
To analyse the relation between drug exposure and time from liver diagnosis to the three outcome measures, overall mortality, liver-related mortality and liver-related morbidity, we used a marginal structural Cox model to estimate hazard ratios, using inverseprobability-of-treatment weights [12] . This enables us to avoid potential bias from time-dependent confounding. For each outcome and drug exposure, we modelled using the time-fixed confounders age at diagnosis (using restricted cubic spline) and sex, as well as the time-dependent confounders diabetes, hepatitis C, ischaemic heart disease, heart failure and the other drugs. For instance, for the models focusing on statins, we included ACEi, ARB and antibiotics in the calculation of the weights in the marginal structural models. We analysed the overall effects of the outcome measures during the study period, and we present the results as hazard ratios with 95% confidence intervals (CI). For the outcome measures concerning liverspecific mortality and liver-specific morbidity, other events such as death from other causes were treated as censored. In some cases, the assumption of proportional hazards was somewhat violated. We preferred to keep the models parsimonious, not modelling the nonproportionality. The estimated hazard ratios were interpreted as geometric averages of the true hazard ratios [13] .
We first analysed the entire study period. Then, we analysed the first year after treatment initiation and subsequent years, separately. The different confounding diagnoses were defined with the following ICD-10 codes: diabetes (E10 and E11), ischaemic heart disease (I20.0-I25), heart failure (I50) and hepatitis C (B18.2).
Results
We identified 70,546 patients diagnosed with chronic liver disease for the first time at hospitals in Sweden between 2005 and 2012. The most frequent diagnosis groups were other liver diseases, viral hepatitis and alcoholic liver disease. The patient characteristics are presented in table 1. The patients who were exposed to statins, ACEi, ARB and antibiotics are presented in table 2. More than 7000 patients were exposed to each drug group.
Statin users had reduced mortality hazards with significance for alcoholic liver disease, 0.84 (95% CI: 0.75-0.95), and for AIH, 0.57 (95% CI: 0.32-0.99); and with a reduction for liver-specific mortality for both diagnoses. Also, liver-related morbidity hazard was reduced for alcoholic liver disease (95% CI: 0.81-0.97). Patients with PBC and other liver diseases who used statins did have a significant reduction of liverrelated mortality the first year after exposure, 0.36 (95% CI: 0.14-0.98) and 0.75 (95% CI: 0.64-0.87). No significant reduction in overall mortality, liver-related mortality and liverrelated morbidity was observed in patients with NAFLD or toxic liver disease. The hazard ratios are presented in table 3A.
Angiotensin-converting enzyme inhibitors decreased the liver-related mortality hazards in patients with alcoholic liver disease, 0.85 (95% CI, 0.75-0.96), and a reduction was seen for liver-related morbidity in viral hepatitis, 0.18 (95% CI, 0.03-0.94). ARB did not affect mortality or morbidity hazard ratios for autoimmune hepatitis, PBC and toxic and other liver diseases. We found only a reduction in hazard risk for liverrelated mortality after the first year after exposure in other liver diseases, 0.64 (95% CI: 0.51-0.81), for patients who were exposed to ACEi. The hazard ratios are presented in table 3B,C. For antibiotics, an increased hazard was seen in overall mortality for all liver diseases, 1.67 (95% CI, 1.55-1.80), and in liver-specific mortality (1.41 (95% CI, 1.24-1.61)) and liver-related morbidity (1.05 (95% CI: 1.02-1.08)) for viral hepatitis, while liver-related mortality and morbidity hazard ratios were not influenced for the other diagnoses. The hazard ratios are presented in table 3D.
Discussion
The main finding in this study was that statin use was associated with reduced risks of overall mortality, liver-specific mortality and liver-specific morbidity for several diagnoses. We also found that ACEi were associated with decreased risks of liver-specific mortality and liver-specific morbidity for alcoholic liver disease and a reduction in liver-related morbidity in viral hepatitis.
Statins decrease the expression of iNOS, alpha-smooth muscle antibodies and collagen I and induce expression of eNOS in NASH rats [14] . Atorvastatin treatment inhibits proliferation, apoptosis and cytokine production of stellate cells in bile duct-ligated (BDL) rats [15] . Atorvastatin blunts the increase in inflammatory infiltration, oxidative stress and hepatic cell activation in angiotensin-induced rats [16] . Prophylactic and early therapy with atorvastatin has been shown to significantly attenuate fibrosis and stellate cell activation. Later therapy did not show significant effects on fibrosis but reduced profibrotic cytokine expression and led to a more quiescent state of HSC with less proliferation and apoptosis, while hepatic inflammation did not change [17] . Statins may affect immunomodulation through different mechanisms such as nuclear factor-jB and pro-inflammatory cytokines [18, 19] . They may improve endothelial function, decrease oxidative stress and increase endothelial nitric oxide and vasodilation, with a suggested beneficial effect on intrahepatic vascular resistance [14, [20] [21] [22] . Simvastatin has shown improved hepatic function and reduction in liver fibrosis in rats [23] . Clinical trials have indicated a beneficial effect of statins in hepatitis C and NAFLD [24] [25] [26] [27] [28] [29] . Furthermore, statins decreased liver decompensation in cirrhotics, reduced hepatic venous pressure gradient and lowered the rate of hospitalizations for infections in patients with compensated cirrhosis [30] [31] [32] . In a cohort of patients with chronic liver diseases, atorvastatin users had a mortality risk reduction comparable to our results [33] . Statins have been associated with a lower risk of developing hepatocellular cancer [34] [35] [36] . There have also been studies showing no effect or opposing effects of statin treatment [37] . Patients with primary biliary cirrhosis and autoimmune hepatitis showed less improvement in survival associated with statin treatment compared with the other diagnoses. PBC has a different pathogenesis compared to the other chronic liver diseases, often lacking a necro-inflammatory component [38] . Statins mainly attenuate the necro-inflammatory process, which may explain the lack of effect seen in patients with PBC. Taken together, statins have several effects inhibiting HSC activation and inflammatory processes, and reducing fibrosis progression, which may explain the reduced risks seen in our nationwide study.
We also found an association between the use of ACEi and an improved liver-related mortality and morbidity in alcoholic liver disease and viral hepatitis. Earlier studies have shown that patients receiving ARB and ACEi had significantly less fibrosis than those receiving other antihypertensive agents [39] [40] [41] . An explanation could be reduced up-regulation of angiotensin-converting enzyme and angiotensin receptor gene (AT1) in hepatic fibrogenesis and of AT1 receptor activation leading to HSC proliferation [42] . In hypertensive patients with NAFLD, ACEi or ARB were associated with less advanced fibrosis [43] . Candesartan and ursodeoxycholic acid in combination led to histological improvement in fibrosis compared to ursodeoxycholic acid alone [44] . Both ACEi and ARB decreased portal pressure in cirrhosis in one study, while in others no such effect was demonstrated [45] [46] [47] [48] . Previous data have shown that ACEi have several effects inhibiting HSC activation, decreasing portal hypertension and slowing fibrosis progression by reducing the effect of angiotensin II on the activity and proliferation of hepatic stellate cells [9, 45, [49] [50] [51] [52] . These effects may explain the reduced hazard ratios for liver-related mortality and liver-related morbidity in the present study. A positive trend in overall and liver-related mortality is observed for both ACEi and ARB (although not significant). This pattern could be caused by competing risks -with a higher proportion of cardiovascular mortality corresponding to the indication of the drugs.
Antibiotics are prescribed for bacterial infections that are known to worsen the course of liver cirrhosis. The increased risk in overall and liver-specific mortality for some diagnoses is therefore expected. In addition, antibiotics are a diverse group and some are used to treat spontaneous bacterial peritonitis, thus associated with a more severe prognosis. The most likely explanation for the effects seen for antibiotics is that the use of antibiotics is a marker of infections which Number of patients exposed to our drug groups and percentage of exposed patients for all diagnosis groups. worsen the prognosis for liver diseases. Access to health care might be a confounder for our results, but the decreased survival after exposure to antibiotics argues against such an explanation. Our study has several strengths. We examined a large cohort with 70,546 patients where many patients were exposed to the investigated drug groups. The health registers in Sweden are of high quality; the diagnoses are valid and the risk of selection bias is minimal because the registers have complete coverage as all Swedish hospitals and outpatient hospital services must register all their discharges and outpatient visits, and loss to follow-up is minimized [10] . The SPDR is linked to the personal identity number, so no prescription can be dispensed without it [11] . All patients with liver disease diagnosed for the first time during the study period, exposures and outcome measures have been covered, and the risk estimates are probably representative of patients with the liver diseases we have studied. We adjusted for known risk factors for fibrosis such as diabetes and hepatitis C, and we also adjusted for the diagnosis of ischaemic heart disease and heart failure. We found consistent patterns of effects of the respective drug groups we studied in most diagnosis groups. This probably implies that we have real pharmacological effect on liver fibrosis progression.
We acknowledge some limitations. We do not have any information on the liver disease stages or the number of patients with decompensation symptoms. Treatment could be withheld in patients with severe liver disease, thus explaining some of the associations seen in our study. We did not evaluate all other dispensed medications, or all other diagnoses or diseases that might have interacted with the mortality or morbidity risks. However, we adjusted the analyses for ischaemic heart disease, heart failure, diabetes and hepatitis C, but there could have been residual confounding from ongoing alcohol abuse, smoking and obesity. We deferred from using hospitalized for alcohol dependence as a marker of heavy alcohol consumption because only a small part of all of the persons with heavy consumption would have been hospitalized in Sweden. As for overweight, we do not have BMI data in the Patient Register in Sweden. Medication use in nursing homes and hospitals is not included in the SPDR but constitutes only a small fraction of prescribed medication in Sweden and is therefore unlikely to have influenced the results substantially [53] . We defined exposure as at least two dispensations during a 12-month period, which indicates compliance. This could reduce the effects seen as exposed patients are more adherent to regular follow-up and general health advice that may improve their prognosis. A healthy adherer bias could also be a possibility. One major strength of this study is the use of national registers with high coverage of the population for hospitalizations (99% primary diagnoses of all hospital discharges) and complete coverage for dispensed prescribed drugs, and minimal loss to follow-up [10, 53] . Another strength is that a hospital physician independent of dispensed prescribed drugs at the pharmacies diagnosed the outcome measures. In addition, data on dispensed drugs are a step closer to actual drug consumption than information on prescribed drugs in medical records. Several p-values are reported in the tables, and there may be overall type I errors. We concede that some of the p-values may fall below a 0.05 threshold by chance. The unexposed group could be healthier with less cardiovascular diseases and therefore unexposed to statins, ARB and ACEi. This could lead to an underestimation of the reduction in risk, and the differences between the exposed and unexposed could be higher than those estimated.
In conclusion, we have demonstrated an association between statin use and reduced liver disease morbidity, mortality and reduced overall mortality in a national cohort of patients with alcoholic liver disease and autoimmune hepatitis. A similar but weaker effect was seen in patients treated with ACEi. Our results indicate in addition that antibiotics are associated with increased mortality. Future research should aim to define the characteristics of those patients with liver disease who may benefit from treatment with statins or ACEi. Further studies could use other healthcare databases to corroborate the findings of our study.
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